�����̨

Petro, E., Joosse, I. R., Siebers, A. C. M., Martopullo, T., Hart, R. P. M., Mantel-Teeuwisse, A. K., van den Ham, H. A., & Suleman, F. (2025). Time and cost involved in measuring access to medicines: the case of Albania. BMC Research Notes, 18(1), Article 104.

Chen, M., Kuzyakov, Y., Zhou, J., Zamanian, K., Wang, S., Abdalla, K., Wang, J., Li, X., Li, H., Zhang, H., Mganga, K. Z., Li, Y., & Blagodatskaya, E. (2025). High soil salinity reduces straw decomposition but primes soil organic carbon loss. Soil Biology and Biochemistry, 207, 1-11. Article 109835.

Miguel, J. W. A. M., van Veen, N. L., Jacobs, W., Damhuis, R. A. M., van Uden-Kraan, C. F., & van de Garde, E. M. W. (2025). Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019–2020: A nationwide study. Cancer Epidemiology, 96, Article 102809.

Jansen-Groot Koerkamp, E. A. W., Simsek, I., Badawy, E., Heringa, M., & Bouvy, M. L. (2025). Patient counselling on opioids by pharmacy technicians: A mixed-method study to explore facilitators and barriers. PEC Innovation, 6, Article 100382.

Davies, L. E. M. (2025). Pain Points: Patient Perspectives on Opioid Treatment for Chronic Pain. [Doctoral thesis 1 (Research �����̨ / Graduation �����̨), �����̨]. Utrecht University.

Meertens, M., Rosing, H., Steeghs, N., Beijnen, J. H., & Huitema, A. D. R. (2025). Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital-Based Towards Home-Sampling. Biomedical Chromatography, 39(5), Article e70056.

de Haart, K., Asao, K., Ataher, Q., Geier, J., Hillen, J., Huang, K., Mol, P. G. M., Rivera, D., Wang, H., Yang, H., Zhan, S., Hoogendoorn, W. E., & Bloem, L. T. (2025). Long-term follow-up after authorization of gene therapy: leveraging real-world data. Drug Discovery Today, 30(5), Article 104337.

Liang, D., Paul, A. K., Weir, D. L., Deneer, V. H. M., Greiner, R., Siebes, A., & Gardarsdottir, H. (2025). Methods in dynamic treatment regimens using observational healthcare data: A systematic review. Computer Methods and Programs in Biomedicine, 263, Article 108658.

Houwen, J. P. A., Lalmohamed, A., Zwaan, J., Egberts, T. C. G., Duyvendak, M., Fiolet, A. T. L., & Mosterd, A. (2025). The effect of colchicine on coagulation in patients with chronic coronary disease who use vitamin K antagonists. European Journal of Clinical Pharmacology, 81(5), 719-725.

Opalska, A., Kwa, M., & Leufkens, H. (2025). Implementation of indication restrictions made by European regulatory action for antibiotics - amoxicillin. European Journal of Pharmaceutical Sciences, 209, Article 107106. Advance online publication.

Leung, M. W. Y. (2025). Pharmacoepidemiologic studies of infection among people with multiple sclerosis: Occurrence and effects of pharmacotherapy. [Doctoral thesis 1 (Research �����̨ / Graduation �����̨), �����̨]. Utrecht University.

Essink, S. C. M., Zomerdijk, I. M., Straus, S. M. J. M., Gardarsdottir, H., & De Bruin, M. L. (2025). Risk Minimisation Measures of Advanced Therapy Medicinal Products Authorised in the EU Between 2009 and 2023: A Cross-Sectional Study. Drug Safety. Advance online publication.

Postma, D. J., De Smet, P. A. G. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Notenboom, K. (2025). Upstream pharmaceutical supply chains of 10 high-use pharmaceuticals in the Netherlands: a cohort study. BMJ Open, 15(4), Article e099697.

Jacobs, T. G., Ooms, G. I., Mantel-Teeuwisse, A. K., & Suleman, F. (2025). Commentary: Pediatric HIV Treatment: Nurturing Access Through Health Facility Availability and Stock-out Monitoring. Pediatric Infectious Disease Journal. Advance online publication.

Westein, M. P. D. (2025). Training and Assessment in Workplace-based Community Pharmacy: Creating Foundations and Nurturing Progress. [Doctoral thesis 1 (Research �����̨ / Graduation �����̨), �����̨]. Utrecht University.

MOLecular Evaluation of Melanocytic Ambiguous Tumours (MOLEMAT) Investigators, Ebbelaar, C. F., Jansen, A. M. L., Speet, L. C. M., Schutgens, F., Zoetemeyer, S., Cleton-Jansen, A.-M., van Dijk, M. R., Breimer, G. E., Bloem, L. T., de Leng, W. W. J., van Doorn, R., Suijkerbuijk, K. P. M., Schrader, A. M. R., & Blokx, W. A. M. (2025). Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours. EBioMedicine, 114, Article 105643.

Tataru, E. A., Dooms, M., Gonzaga-Jauregui, C., Pasmooij, A. M. G., O'Connor, D. J., & Jonker, A. H. (2025). Drug–device combinations in rare diseases: Challenges and opportunities. Drug Discovery Today, 30(4), Article 104343.

Essink, S. C. M., Zomerdijk, I. M., Goedecke, T., Straus, S. M. J. M., Gardarsdottir, H., & De Bruin, M. L. (2025). Duration of Time Intervals for Risk Minimization Measure Effectiveness Studies. Clinical Pharmacology and Therapeutics, 117(4), 1106-1114.

Emond, S. K., Goettsch, W. G., & Ollendorf, D. A. (2025). Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability. Clinical Pharmacology and Therapeutics, 117(4), 938-945.

Krishna, R., Jonker, A. H., Morel, T., Sakushima, K., Pasmooij, A. M. G., & O'Connor, D. (2025). IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases. Nature Reviews Drug Discovery, 24(4), 233-234.

Ensing, H. T., Kurt, N., Janssen, R. A., Koster, E. S., & Heerdink, E. R. (2025). Pharmacist-led new medicine service: a real-world cohort study in the Netherlands on drug-related problems, satisfaction, and self-efficacy in cardiovascular patients transitioning to primary care. International Journal of Clinical Pharmacy, 47(2), 325–334.

Saylor, D., Rijke, N., McDonell, J., Laurson-Doube, J., Avasarala, J., Baldin, E., Banerjee, T. K., Bogdanovic, I., Bove, R., Chawla, D. K., Costello, K., Del Giovane, C., Abkari, N. E., Filippini, G., Foschi, M., Gonzalez-Lorenzo, M., Helme, A., Jacobs, D., Kalincik, T., ... Piggott, T. (2025). Recommendations for essential medicines for multiple sclerosis in low-resource settings. Multiple Sclerosis Journal, 31(4), 454-473.

van Loon, E., Heringa, M., Floor-Schreudering, A., de Smet, P., & Bouvy, M. (2025). Relevance of therapeutic prescription modifications in Dutch community pharmacies. The International Journal of Pharmacy Practice, 33(2), 169-179.

Lu, Z., Dong, B., Cai, H., Tian, T., Wang, J., Fu, L., Wang, B., Zhang, W., Lin, S., Tuo, X., Wang, J., Yang, T., Huang, X., Zheng, Z., Xue, H., Xu, S., Liu, S., Sun, P., & Zou, H. (2025). Identifying Data-Driven Clinical Subgroups for Cervical Cancer Prevention With Machine Learning: Population-Based, External, and Diagnostic Validation Study. JMIR Public Health and Surveillance, 11, Article e67840.

Kanning, J. P., Wang, J., Abtahi, S., Geerlings, M. I., & Ruigrok, Y. M. (2025). Identifying novel risk factors for aneurysmal subarachnoid haemorrhage using machine learning. Scientific Reports, 15(1), Article 9256.

Costa, E., Del Grosso, V., Cappello, B., Genazzani, A. A., Huttner, B., Leufkens, H. G. M., Magrini, N., Nonino, F., Wirtz, V. J., van den Ham, H. A., & Moja, L. (2025). Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study. Frontiers in Medicine, 12, Article 1517020.

Engelen, E. M. C., Knol, W., Wuyts, S. C. M., Theunissen, D. A., Vondeling, A. M., Cooijmans, S., van Herwaarden, N., Kramers, C., van den Bemt, P. M. L. A., van Agtmael, M. A., & Bouvy, M. L. (2025). Older patients' experiences and needs regarding pharmacotherapeutic care in-hospital and after discharge. Patient Education and Counseling, 136, Article 108754. Advance online publication.

Beex-Oosterhuis, M. M., Lau, S. F. C., van Kesteren, C., Verloop, S., Grootens, K. P., Faber, G., Van Gool, A. R., Heerdink, E. R. R., van Marum, R. J., & Touw, D. J. (2025). The Impact of Once Daily Dosing on Protein Binding of Clozapine and Norclozapine. Journal of Clinical Psychopharmacology. Advance online publication.

Hogervorst, M. A., Vreman, R. A., Oduol, T. A., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Kesselheim, A. S. (2025). Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis. Clinical Pharmacology and Therapeutics. Advance online publication.

van der Heijden, L. T., Tibben, M. M., Ali, M. I. M., Aardenburg, L. G. J., Steeghs, N., Beijnen, J. H., Rosing, H., & Huitema, A. D. R. (2025). An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 2H6-alectinib and alectinib in human plasma to support a microtracer food-effect trial. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1253, Article 124488.

Lievense, J. J., Nijenhuis, C., Jedema, I., Jonker-Hoogerkamp, A., Moyers, J. T., Hamid, O., Beijnen, J. H., Haanen, J. B. A. G., & Nuijen, B. (2025). Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products. Transplantation and Cellular Therapy, 31(3), S610-S625.

Verschueren, M. V., Tassopoulou, V. P., Visscher, R., Schuurkamp, J., Peters, B. J. M., Koopman, M., van de Garde, E. M. W., Egberts, A. C. G., & Bloem, L. T. (2025). Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review. ESMO Real World Data and Digital Oncology, 7, Article 100118.

Smit, J. M., Van Der Zee, P. A., Stoof, S. C. M., Van Genderen, M. E., Snijders, D., Boersma, W. G., Confalonieri, P., Salton, F., Confalonieri, M., Shih, M.-C., Meduri, G. U., Dequin, P.-F., Le Gouge, A., Lloyd, M., Karunajeewa, H., Bartminski, G., Fernández-Serrano, S., Suárez-Cuartín, G., van Klaveren, D., ... Endeman, H. (2025). Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. The Lancet Respiratory Medicine, 13(3), 221-233.

Lin, L., Lucassen, M. J. J., van der Noort, V., Egberts, T. C. G., Beijnen, J. H., & Huitema, A. D. R. (2025). The feasibility of using real world data as external control arms in oncology trials. Drug Discovery Today, 30(3), Article 104324.

Reesink, D. J., Voskuilen, C. S., van de Garde, E. M. W., Hendricksen, K., Horenblas, S., van Melick, H. H. E., & van Rhijn, B. W. G. (2025). Survival in Responders and Nonresponders of Neoadjuvant and Induction Chemotherapy in Invasive Urothelial Carcinoma of the Urinary Bladder: A Clinical and Pathological Stage-Matched Analysis. Clinical Genitourinary Cancer, Article 102319. Advance online publication.

Callenbach, M. H. E. (2025). Fertile Grounds for Outcome-based Managed Entry Agreements? Potential suitability and desirability for highly priced novel therapies. [Doctoral thesis 1 (Research �����̨ / Graduation �����̨), �����̨]. Utrecht University.

Leung, M. W. Y., Garde, E. M. W. V. D., Uitdehaag, B. M. J., Klungel, O. H., & Bazelier, M. T. (2025). The relative risk of infection in people with multiple sclerosis using disease-modifying treatment: a systematic review of observational studies. Neurological Sciences. Advance online publication.

Dong, B., Lu, Z., Yang, T., Wang, J., Zhang, Y., Tuo, X., Wang, J., Lin, S., Cai, H., Cheng, H., Cao, X., Huang, X., Zheng, Z., Miao, C., Wang, Y., Xue, H., Xu, S., Liu, X., Zou, H., & Sun, P. (2025). Development, validation, and clinical application of a machine learning model for risk stratification and management of cervical cancer screening based on full-genotyping hrHPV test (SMART-HPV): a modelling study. The Lancet Regional Health - Western Pacific, 55, Article 101480.

Lasys, T., Santa-Ana-Tellez, Y., Siiskonen, S. J., Groenwold, R. H. H., & Gardarsdottir, H. (2025). Impact of Pharmacovigilance Interventions Targeting Fluoroquinolones on Antibiotic Use in the Netherlands and the United Kingdom. Pharmacoepidemiology and Drug Safety, 34(2), Article e70081.

Davies, L. E. M., van den Ham, H. A., Schellekens, A. F. A., Philbert, D., & Bouvy, M. L. (2025). Patient satisfaction with prescription opioid education in primary care. Patient Education and Counseling, 131, Article 108572.

Trials@Home Consortium, de Jong, A. J., Zuidgeest, M. G. P., Santa-Ana-Tellez, Y., Hallgreen, C. E., van Sloten, T. T., de Boer, A., & Gardarsdottir, H. (2025). The impact of operational trial approaches on representativeness: Comparison of decentralized clinical trial participants, conventional trial participants, and patients in daily practice. Drug Discovery Today, 30(2), Article 104304.

Verschueren, M. V., Hiensch, D. T. A., Plomp, P. M. J., Kastelijn, L. A., van de Garde, E. M. W., & Peters, B. J. M. (2025). Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients. Clinical Lung Cancer. Advance online publication.

Van Gelder, T. G., Vergoossen, D., Zonnenberg, I. A., Lalmohamed, A., Koole-Oostveen, M. I., van Reij, E. M. L., van Loon, A., & Egberts, T. C. G. (2025). Physical compatibility of insulin aspart, lidocaine, alprostadil and vancomycin with individualised two-in-one parenteral nutrition used in the neonatal intensive care unit. European Journal of Hospital Pharmacy, Article ejhpharm-2024-004300. Advance online publication.

de Jong, A. J., Gardarsdottir, H., Santa-Ana-Tellez, Y., de Boer, A., & Zuidgeest, M. G. (2025). Experiences with low-intervention clinical trials-the new category under the European Union Clinical Trials Regulation. Clinical Trials. Advance online publication.

Schultze, A., Martin, I., Messina, D., Bots, S., Belitser, S., Carreras-Martínez, J. J., Correcher-Martinez, E., Urchueguía-Fornes, A., Martín-Pérez, M., García-Poza, P., Villalobos, F., Pallejà-Millán, M., Bissacco, C. A., Segundo, E., Souverein, P., Riefolo, F., Durán, C. E., Gini, R., Sturkenboom, M., ... Douglas, I. (2025). Corrigendum to “A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases” [Vaccine 42 (12) (2024) 3039–3048, (S0264410X2400330X), (10.1016/j.vaccine.2024.03.043)]. Vaccine, 44, 126438. Article 126438.

Mertens, J. F., Hessel, M. H. M., Kempen, T. G. H., Böhringer, S., Norbart, A. F., Walinga, C. W., & van Gelder, T. (2025). Evaluation of an interprofessional education program involving medical and pharmacy students: a mixed-method study. BMC Medical Education, 25(1), Article 48.

Kruijtbosch, M., Floor-Schreudering, A., van Leeuwen, E., & Bouvy, M. L. (2025). Fostering moral reflectivity in community pharmacists through moral case deliberation using the dilemma method. International Journal of Clinical Pharmacy. Advance online publication.

Schouten, W. M., Van Bocxlaer, K., Rosing, H., Huitema, A. D. R., Beijnen, J. H., Kratz, J. M., Mowbray, C. E., & Dorlo, T. P. C. (2025). Development and validation of ultra-performance liquid chromatography tandem mass spectrometry methods for the quantitative analysis of the antiparasitic drug DNDI-6148 in human plasma and various mouse biomatrices. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1250, 1-11. Article 124377.

Hogervorst, M. A., Soman, K. V., Gardarsdottir, H., Goettsch, W. G., & Bloem, L. T. (2025). Analytical Methods for Comparing Uncontrolled Trials with External Controls from Real-World Data: a Systematic Literature Review and Comparison to European Regulatory and Health Technology Assessment Practice. Value in Health, 28(1), 161-174.

Bots, S. H., Belitser, S., Groenwold, R. H. H., Durán, C. E., Riera-Arnau, J., Schultze, A., Messina, D., Segundo, E., Douglas, I., Carreras, J. J., Garcia-Poza, P., Gini, R., Huerta, C., Martín-Pérez, M., Martin, I., Paoletti, O., Bissacco, C. A., Correcher-Martínez, E., Souverein, P., ... Klungel, O. H. (2025). Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example. American Journal of Epidemiology, 194(1), Article kwae172.

Hermans, A. M. M., Bakker, E., Starokozhko, V., den Otter, L., Elferink, A. J. A., Bradshaw, A., Guizzaro, L., Mol, P. G. M., & Pasmooij, A. M. G. (2025). Biomarkers for neurodegenerative diseases in regulatory decision-making by the European Medicines Agency. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 11(1), Article e70072.

Lips, N., Singh, A., Weir, D., & Karapinar-Carkit, F. (2025). Comparing the performance of multiple trigger tools in identifying medication-related hospital readmissions. Journal of the American Geriatrics Society, 73(1), 162-171.

Bots, S. H., Brown, J., Wong, A. Y. S., Martin, I., Douglas, I., Klungel, O. H., & Schultze, A. (2025). Core Concepts: Self-Controlled Designs in Pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 34(1), Article e70071.

Costa, E., Girotti, S., Mathieu, C., Castellani, C., Ross, J. S., Taylor-Cousar, J. L., & Leufkens, H. G. M. (2025). Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. Journal of Cystic Fibrosis, 24(1), 125-132.

Zhou, G., Dael, N., Verweij, S., Balafas, S., Mubarik, S., Rengerink, K. O., Pasmooij, A. M. G., van Baarle, D., Mol, P. G. M., de Bock, G. H., & Hak, E. (2025). Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024. European Respiratory Review, 34(175), Article 240222.

Dutch CDSS‐efficiency study group, Graafsma, J., van de Garde, E. M. W., Derijks, H. J., Hoge, R. H. L., Klopotowska, J. E., Karapinar-Carkit, F., & van den Bemt, P. M. L. A. (2025). Efficiency of computerized clinical decision support systems involving anticoagulants: A flashmob study in Dutch hospital pharmacies. British Journal of Clinical Pharmacology, 91(1), 157-165.

Costa, E., Ware, R. E., Tshilolo, L., Makani, J., Leufkens, H. G. M., & Luzzatto, L. (2025). Globalization in clinical drug development for sickle cell disease. American Journal of Hematology, 100(1), 4-9.

Jansen, M. S., Dekkers, O. M., Cessie, S. L., Hooft, L., Gardarsdottir, H., de Boer, A., & Groenwold, R. H. H. (2025). Multiple Perspectives on the Need for Real‐World Evidence to Inform Regulatory and Health Technology Assessment Decision‐Making: Scoping Review and Stakeholder Interviews. Pharmacoepidemiology and Drug Safety, 34(1), 1-16. Article e70074.

Scholte, M., Grimm, S. E., Pauly, B., Verbeeck, F., Pasmooij, A. M. G., Bouma, B., van Duijn-Wiersma, J., Guney, E., Kesselheim, A. S., Schmidt, H. H. H. W., & Joore, M. A. (2025). Revising EU pharmaceutical legislation: will it foster drug repurposing? Drug Discovery Today, 30(1), Article 104286.

Bloem, L. T., Leufkens, H. G. M., Berends, S. E., Vreman, R. A., Hollak, C. E. M., van Weely, S., de Lannoy, L. M., Bertens, P. J. A., & Pasmooij, A. M. G. (2025). Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value? Drug Discovery Today, 30(1), Article 104251.

Møllebæk, M., Gardarsdottir, H., Bikou, A. G., Kodrič, A., Silva, A. M., Andersen, A., Kontogiorgis, C., Poplavska, E., Ahmadizar, F., Dermiki-Gkana, F., Rutkovska, I., Vaz, I. R., Kos, M., Barão, P., Grupstra, R., Alves, T. L., & Almarsdóttir, A. B. (2025). Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study. Drug Safety, 48(2), 161–177.

Wang, Y. G., Gan, C. P., Beukers-Korver, J., Rosing, H., Li, W. L., Wagenaar, E., Lebre, M. C., Song, J. Y., Pritchard, C., Bin Ali, R., Huijbers, I., Beijnen, J. H., & Schinkel, A. H. (2025). Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice. Acta Pharmacologica Sinica, 46(3), 777–793. Article 25747.

Callenbach, M. H. E., Vreman, R. A., Leopold, C., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2025). Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. PharmacoEconomics, 43(1), 53-66. Article 103433.

Kaymakci, B., Philbert, D., Hazen, A. C. M., Heringa, M., Kwint, H. F., Zwart, D. L. M., van Dijk, L., Kälvemark Sporrong, S., & Kempen, T. G. H. (2025). Pharmacists’ perspectives on potential pharmacist prescribing: a nationwide survey in the Netherlands. International Journal of Clinical Pharmacy, 47(2), 392–402. Article e2421993.

on behalf of The N-of-1 Task Force of the International Rare Diseases Research Consortium (IRDiRC), Jonker, A. H., Tataru, E. A., Graessner, H., Dimmock, D., Jaffe, A., Baynam, G., Davies, J., Mitkus, S., Iliach, O., Horgan, R., Augustine, E. F., Bateman-House, A., Pasmooij, A. M. G., Yu, T., Synofzik, M., Douville, J., Lapteva, L., Brooks, P. J., ... Aartsma-Rus, A. (2025). The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Nature Reviews Drug Discovery, 24(1), 40-56. Article e10486.

Schmidt, M., Vernooij, R., van Nuland, M., Smeijsters, E., Devriese, L., Mohammad, N. H., Hermens, T., Stammers, J., Swart, C., Egberts, T., Haitjema, S., & Lammers, L. (2024). Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival. BMC Cancer, 24(1), Article 1553.

Wolthuis, D. F. G. J., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A. M., Guchelaar, H. J., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Swen, J. J., Touw, D. J., van Westrhenen, R., Deneer, V. H. M., & Houwink, E. J. F. (2024). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas. European Journal of Human Genetics. Advance online publication.

Hunt, N. B. (2024). Multi-Database Methodologies to Enhance Real-World Evidence Generation. [Doctoral thesis 1 (Research �����̨ / Graduation �����̨), �����̨]. Utrecht University.

Leung, M. W. Y., Bazelier, M. T., Uitdehaag, B. M. J., De Jong, H. J. I., Klungel, O. H., & van de Garde, E. M. W. (2024). Antibiotic Utilization Among People With Multiple Sclerosis in the Netherlands, 2018–2020. Pharmacoepidemiology and Drug Safety, 33(12), Article e70070.

Mohmaed Ali, M. I., Nijstad, A. L., Boosman, R. J., Crombag, M. R. B. S., Barnett, S., Veal, G. J., Lalmohamed, A., van Erp, N. P., Steeghs, N., Zwaan, C. M., Beijnen, J. H., Siebinga, H., & Huitema, A. D. R. (2024). A Population Pharmacokinetic Study to Evaluate Doxorubicin Exposure Across All Age Groups. Clinical Pharmacokinetics, 63(12), 1711-1722.

Falke, C., Karapinar, F., Bouvy, M., Emmelot, M., Belitser, S., Boland, B., O'Mahony, D., Murphy, K. D., Haller, M., Salari, P., Schwenkglenks, M., Rodondi, N., Egberts, T., & Knol, W. (2024). Correction: The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy. European Geriatric Medicine, 15, 1725-1730.

Iversen, D. B., Dunvald, A.-C. D., Ernst, M. T., Abtahi, S., Souverein, P., Klungel, O., Jeppesen, G. B., Nielsen, F., Brøsen, K., Hammer, H. S., Pötz, O., Damkier, P., Järvinen, E., Pottegård, A., & Stage, T. B. (2024). Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users. British Journal of Clinical Pharmacology, 90(12), 3252-3262.

Zinken, J. F., Pasmooij, A. M. G., Ederveen, A. G. H., Hoekman, J., & Bloem, L. T. (2024). Environmental risk assessment in the EU regulation of medicines for human use: an analysis of stakeholder perspectives on its current and future role. Drug Discovery Today, 29(12), Article 104213.

van Vliet, E., Lipovec, N. Č., van der Goot, M., Abtahi, S., Ribeiro-Vaz, I., Poplavska, E., Dermiki-Gkana, F., Oikonomou, C., Deligianni, E., Kontogiorgis, C., Silva, A. M., Ferreira, P. B. S., Kos, M., Almarsdóttir, A. B., Jacobsen, R., Buhl, C., de Bruijn, A., Hegger, I., & Alves, T. L. (2024). Impact of Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syndrome for COVID-19 Adenovirus Vector Vaccines on European Healthcare Professionals. Pharmacoepidemiology and Drug Safety, 33(12), Article e70057.

Coppes, T., Philbert, D., Van Riet, M., van Gelder, T., Bouvy, M., & Koster, E. (2024). Medication management during risk of dehydration: A qualitative study among elderly patients with impaired renal function and informal caregivers. European Journal of General Practice, 30(1), Article 2413097.

Luijken, K., Morzywołek, P., van Amsterdam, W., Cinà, G., Hoogland, J., Keogh, R., Krijthe, J. H., Magliacane, S., van Ommen, T., Peek, N., Putter, H., van Smeden, M., Sperrin, M., Wang, J., Weir, D. L., Didelez, V., & van Geloven, N. (2024). Risk-Based Decision Making: Estimands for Sequential Prediction Under Interventions. Biometrical Journal, 66(8), Article e70011.

Taams, A. C., Herberts, C. A., Egberts, A. C. G., Zafiropoulos, N., Pignatti, F., & Bloem, L. T. (2024). Uncertainties about the benefit-risk balance of oncology medicines assessed by the European Medicines Agency. ESMO Open, 9(12), Article 103991.

van Dam, C. J., Kramers, C., Schellekens, A., Bouvy, M., van Dorp, E., Kowal, M. A., Olofsen, E., Dahan, A., Niesters, M., & van Velzen, M. (2024). Cannabis combined with oxycodone for pain relief in fibromyalgia pain: a randomized clinical self-titration trial with focus on adverse events. Frontiers in Pain Research, 5, 1-10. Article 1497111.

Tamblyn, R., Habib, B., Buckeridge, D. L., Weir, D. L., Frolova, E., Alattar, R., Rogozinsky, J., Beauchamp, C., Pupo, R., Bartlett, S. J., & McDonald, E. (2024). Evaluating the effectiveness of the Smart About Meds (SAM) mobile application among patients discharged from hospital: protocol of a randomised controlled trial. BMJ Open, 14(11), Article e084492.

Jiu, L., Wang, J., Versteeg, J.-W., Zhang, Y., Liu, L., Somolinos-Simón, F. J., Tapia-Galisteo, J., García-Sáez, G., Hogervorst, M. A., Li, X., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Roadmap to Innovation of HTA Methods (IHTAM): insights from three case studies of quantitative methods. International Journal of Technology Assessment in Health Care, 40(1), 1-10. Article e49.

Elvidge, J., Crabb, N., Delnoij, D., Knies, S., Lundin, D., Houÿez, F., Röning, J., Wang, J., Jiu, L., Bennett, A., Zhang, Y., & Dawoud, D. (2024). Implementing a sandbox approach in health technology assessment: Benefits and recommendations. International Journal of Technology Assessment in Health Care, 40(1), Article e44.

Troost, I., van den Bosch, L. J., Nederlof, N., Nazar, S., Wijers, M., Bakker, A., & Pieters, T. (2024). Student assistants as mentor-participants: A case study of distributing leadership in academic co-design education. Frontiers in Education, 9, Article 1389065.

Stoelinga, J., Bloem, L. T., Russo, M., Kesselheim, A. S., & Feldman, W. B. (2024). Comparing supplemental indications for cancer drugs approved in the US and EU. European Journal of Cancer, 212, Article 114330.

Beunk, L., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A.-M., Guchelaar, H.-J., Houwink, E. J. F., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Swen, J. J., Touw, D., Deneer, V. H. M., & van Westrhenen, R. (2024). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants. European Journal of Human Genetics, 32(11), 1371-1377.

Brinkhuis, F., Ruof, J., Ham, H. V. D., Gianfrate, F., Strammiello, V., Berntgen, M., Pavlovic, M., Mol, P. G. M., Wasem, J., Dyck, W. V., Cardone, A., Dierks, C., Schiel, A., Solà-Morales, O., Goettsch, W., & Julian, E. (2024). Evaluating progress towards implementation of the European HTA Regulation: Insights generated from the European Access Academy's multi-stakeholder survey. Health Policy and Technology, 13(5), Article 100930.

van Hattem, C. C., de Jong, A. J., de Groot, J. S., Hoekman, J., Broekman, K. E., Sonke, G. S., van Hennik, P. B., & Bloem, L. T. (2024). Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study. BMJ Open, 14(11), Article e084483.

Jadoenathmisier, K. D., Stoyanova-Beninska, V., Soons, I. M., Leufkens, H. G., Bloem, L. T., & Pasmooij, A. M. (2024). Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union. European Journal of Pharmaceutical Sciences, 202, Article 106871.

Jansen-Groot Koerkamp, E. A. W., Weesie, Y. M., Heringa, M., Hek, K., Blom, J. W., Numans, M. E., van Dijk, L., & Bouvy, M. L. (2024). General practitioners' and community pharmacists' beliefs and practices on opioids for non-malignant pain. European Journal of Pain (United Kingdom), 28(10), 1719-1731.

Grupstra, R. J., Goedecke, T., & Gardarsdottir, H. (2024). Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety Studies. Clinical Pharmacology & Therapeutics, 116(5), 1252-1258.

Avşar, T. S., Elvidge, J., Hawksworth, C., Kenny, J., Németh, B., Callenbach, M., Ringkvist, J., & Dawoud, D. (2024). Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe. Value in Health, 27(11), 1497-1506.

de Jong, A. J., Zuidgeest, M. G. P., Santa-Ana-Tellez, Y., de Boer, A., Gardarsdottir, H., & Trials@Home Consortium (2024). Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches. Drug Discovery Today, 29(11), Article 104180.

Canto, E. D., Uijl, A., Onland-Moret, N. C., Bots, S. H., Hofstra, L., Tulevski, I., Asselbergs, F. W., van der Harst, P., Somsen, G. A., & den Ruijter, H. M. (2024). Simplification of a registry-based algorithm for ejection fraction prediction in heart failure patients: Applicability in cardiology centres of the Netherlands. PLoS One, 19(11), Article e0310023.

van Hulten, V., Souverein, P. C., Starup-Linde, J., Viggers, R., Klungel, O. H., Vestergaard, P., Brouwers, M. C. J. G., van den Bergh, J. P., & Driessen, J. H. M. (2024). The association of type 2 diabetes-related characteristics with fracture risk at different sites. Diabetes, Obesity and Metabolism, 26(11), 4887-4896.

Pieters, T. (2024). Al ruime eeuw vinger aan de pols bij opioïdgebruik. Pharmaceutisch Weekblad, 159(43), 16-19.

van de Plas, A., Tanis, W. J., Deneer, V. H. M., Olsder, G., van der Lee, M. J., Hunfeld, N. G. M., Duyvendak, M., Karapinar-Çarkit, F., Rennenberg, R., & van den Bemt, P. M. L. A. (2024). RISICOGEST�����̨RDE BENADERING OVERTROEFT DE DUBBELCHECK. Pharmaceutisch Weekblad, 159(42), 19-21.

Lentzas, A., Venekamp, N., Beijnen, J. H., & van Tellingen, O. (2024). Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1247, Article 124308.

Bognàr, T., Garcia-Rosa, M., Lalmohamed, A., Güngör, T., Hauri-Hohl, M. M., Prockop, S. E., Oram, L. M., Pai, S.-Y., Brooks, J., Savic, R. M., Dvorak, C. C., Long-Boyle, J. R., Krajinovic, M., Bittencourt, H., Teyssier, A.-C., Theoret, Y., Martinez, C., Egberts, T. C. G., Morales, E., ... Bartelink, I. H. (2024). Association of Busulfan Exposure and Outcomes after HCT for Patients with an Inborn Error of Immunity. Blood advances, 8(19), 5137-5145.

de Jong, A. J. (2024). Bringing clinical trials home: European regulatory perspectives on decentralized clinical trial approaches. [Doctoral thesis 1 (Research �����̨ / Graduation �����̨), �����̨]. Utrecht University.

Verschueren, M. V., Abedian Kalkhoran, H., Deenen, M., van den Borne, B. E. E. M., Zwaveling, J., Visser, L. E., Bloem, L. T., Peters, B. J. M., & van de Garde, E. M. W. (2024). Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non-Small Cell Lung Cancer. JCO clinical cancer informatics, 8, Article e2400053.

Ogar, C. K., Gilbert, H. N., Bloem, L. T., Leopold, C., Bassi, P. U., Katagum, Y. M., Osakwe, A. I., Opadeyi, A. O., Oreagba, I., Mbo, D. N. D., Mantel-Teeuwisse, A. K., & De Bruin, M. L. (2024). Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study. Vaccine, 42(23), Article 126196.

Van De Burgt, B. W. M., Wasylewicz, A. T. M., Dullemond, B., Jessurun, N. T., Grouls, R. J. E., Bouwman, R. A., Korsten, E. H. M., & Egberts, T. C. G. (2024). Development of a text mining algorithm for identifying adverse drug reactions in electronic health records. JAMIA Open, 7(3), Article ooae070.

Smale, E. M., Ottenbros, A. B., van den Bemt, B. J. F., Heerdink, E. R., Verploegen, J., van Zelm, R., Egberts, T. C. G., & Bekker, C. L. (2024). Environmental Outcomes of Reducing Medication Waste by Redispensing Unused Oral Anticancer Drugs. JAMA network open, 7(10), Article e2438677.

Cam, H., Franzon, K., Sporrong, S. K., Kempen, T. G. H., Bernsten, C., Nielsen, E. I., Gustavsson, L., Moosavi, E., Lindmark, S., Ehlin, U., Sjölander, M., Lindner, K. J., & Gillespie, U. (2024). 'You're Just Thinking About Going Home': Exploring Person-Centred Medication Communication With Older Patients at Hospital Discharge. Health expectations : an international journal of public participation in health care and health policy, 27(5), Article e70065.

Bognàr, T., Bartelink, I. H. I., van der Elst, K. C. M., Kingma, J. S., Smeijsters, E. H., Lindemans, C. A. C., Egberts, A. C. G. T., Kuball, J. H. E., de Witte, M. A., De Vries Schultink, A. H. M., & Lalmohamed, A. (2024). Busulfan exposure target attainment in adults undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiple day therapeutic drug monitoring regimen. Transplantation and Cellular Therapy, 30(10), 1007.e1-1007.e10.

van Loon, W. E., Lambert, M., Heringa, M., Bouvy, M. L., & Taxis, K. (2024). Community pharmacists' attitudes towards checking prescriptions: a cross-sectional survey. The International Journal of Pharmacy Practice, 32(5), 363-368. Article riae030.

Opalska, A., Gardarsdottir, H., Kwa, M., Wójkowska‑Mach, J., Sabate, M., Ballarin, M. E., de Groot, M., & Leufkens, H. (2024). Correction to: Use of antibiotics in the early COVID-19 pandemic in Poland, the Netherlands and Spain, from erraticism to (more) logic (European Journal of Clinical Pharmacology, (2024), 80, 10, (1581-1589), 10.1007/s00228-024-03726-1). European Journal of Clinical Pharmacology, 80(10), 1591.

DECISION Investigators and Committees, van Veldhuisen, D. J., Rienstra, M., Mosterd, A., Alings, A. M., van Asselt, A. D. J., Bouvy, M. L., Tijssen, J. G. P., Schaap, J., van der Wall, E. E., Voors, A. A., Boorsma, E. M., Lok, D. J. A., Crijns, H. J. G. M., Schut, A., Vijver, M. A. T., Voordes, G. H. D., de Vos, A. H., Maas-Soer, E. L., ... van der Meer, P. (2024). Efficacy and safety of low-dose digoxin in patients with heart failure. Rationale and design of the DECISION trial. European Journal of Heart Failure, 26(10), 2223-2230.

Meijvis, V. A. M., Heringa, M., Kwint, H.-F., de Wit, N. J., & Bouvy, M. L. (2024). Factors influencing the implementation of the CombiConsultation in Dutch clinical practice: a mixed-methods study. International Journal of Pharmacy Practice, 32(5), 347-354.

Pichler, F. B., Boysen, M., Mittmann, N., Gilardino, R., Bruce, A., Bond, K., Vreman, R. A., Largeron, N., Banhazi, J., Ollendorf, D. A., Jain, M., Upadhyaya, S., & Goettsch, W. G. (2024). Lifecycle HTA: Promising applications and a framework for implementation. International Journal of Technology Assessment in Health Care, 40(1), Article e50.

Mertens, J. F., Kempen, T. G. H., Koster, E. S., Deneer, V. H. M., Bouvy, M. L., & van Gelder, T. (2024). Pharmacists and pharmacy students' perceptions on how a new teaching model supports their clinical decision-making. Currents in Pharmacy Teaching and Learning, 16(10), Article 102136.

Versteeg, J.-W., Vreman, R., Mantel-Teeuwisse, A., & Goettsch, W. (2024). Uncertainty In Long-term Relative Effectiveness Of Medicines In Health Technology Assessment: Comparing Assessments Of Medicines For Spinal Muscular Atrophy, Cystic Fibrosis, And Hypercholesterolemia. Value in Health, 27(10), 1358-1366.

Meije, R., Selvanayagam, T., Philbert, D., Bouvy, M., van Tuyll van Serooskerken, A.-M., Haeck, I., & Gemmeke, M. (2024). Betere eczeemzorg dankzij e-learning en informatieboekje: Apothekersassistenten hebben meer zelfvertrouwen bij begeleiden van patiënten. Pharmaceutisch Weekblad, 159(39), 12-13.

Schoenmakers, D. H., van den Berg, S., Timmers, L., Adang, L. A., Bäumer, T., Bosch, A., van de Casteele, M., Datema, M. R., Dekker, H., Donnelly, C., Driessens, M. H. E., Graessner, H., Greger, V., Haddad, T., Höglinger, G. U., van den Hout, H., Jonker, C., Langeveld, M., Lambert, L. J., ... Wolf, N. I. (2024). Framework for Multistakeholder Patient Registries in the Field of Rare Diseases: Focus on Neurogenetic Diseases. Neurology, 103(6), Article e209743.

Houwen, J., Zwaan, J., Egberts, T., Duyvendak, M., Lalmohamed, A., Fiolet, A., & Mosterd, A. (2024). De invloed van colchicine op de bloedstolling bij patiënten met chronische coronaire aandoeningen die vitamine-K antagonisten gebruiken. Pharmaceutisch Weekblad, 159(38), 23-28. Article e1784.

Leopold, C., Hagens, A., Dai, J., Tordrup, D., Dolgorsuren, S., Grafton, D., Huikuri, S., Jung, J., Roberts, E., Stanton, R., Tarlton, D., & Webb, D. (2024). Investment Case for Air Pollution Reduction in Mongolia. UNDP.

Santa-Ana-Téllez, Y., & Elseviers, M. (2024). Comparison of drug utilization across countries. In Drug Utilization Research: Methods and Applications: Second Edition (pp. 260-270). Wiley-Blackwell.

Bennie, M., Kurdi, A., & Santa-Ana-Téllez, Y. (2024). Promoting appropriate use of medicines in a healthcare system. In Drug Utilization Research: Methods and Applications: Second Edition (pp. 248-257). Wiley-Blackwell.

Angerer, E., Burke, M., Dirks, S., Bakker, A., Bilinski Torres, A., & Pieters, T. (2024). The Living Library: a process-based tool for open literature review, probing the boundaries of open science. SN Social Sciences, 4(9), Article 167.

Lin, L., van der Noort, V., Steeghs, N., Ruiter, G., Beijnen, J. H., & Huitema, A. D. R. (2024). A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib. Cancer Chemotherapy and Pharmacology, 94(3), 453-459.

van Nuland, M., Lobbezoo, A.-F. H., van de Garde, E. M. W., Herbrink, M., van Heijl, I., Bognàr, T., Houwen, J. P. A., Dekens, M., Wannet, D., Egberts, T., & van der Linden, P. D. (2024). Assessing accuracy of ChatGPT in response to questions from day to day pharmaceutical care in hospitals. Exploratory Research in Clinical and Social Pharmacy, 15, Article 100464.

Smale, E. M., Verkerk, E. W., Heerdink, E. R., Egberts, T. C. G., van den Bemt, B. J. F., & Bekker, C. L. (2024). Barriers and facilitators to implement the redispensing of unused oral anticancer drugs in clinical care: A hybrid-effectiveness type I study. Exploratory Research in Clinical and Social Pharmacy, 15, Article 100493.

Coppes, T., Hazen, A. C. M., Zwart, D. L. M., Koster, E. S., van Gelder, T., & Bouvy, M. L. (2024). Characteristics and preventability of medication-related admissions for acute kidney injury and dehydration in elderly patients. European Journal of Clinical Pharmacology, 80(9), 1355-1362.

The CHEERS-AI Steering Group, Elvidge, J., Hawksworth, C., Avşar, T. S., Zemplenyi, A., Chalkidou, A., Petrou, S., Petykó, Z., Srivastava, D., Chandra, G., Delaye, J., Gomes, M., Knies, S., Nousios, P., Siirtola, P., Wang, J., & Dawoud, D. (2024). Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI). Value in Health, 27(9), 1196-1205.

Werkman, N. C. C., Driessen, J. H. M., Klungel, O. H., Schaper, N. S., Souverein, P. C., Stehouwer, C. D. A., & Nielen, J. T. H. (2024). Incretin-based therapy and the risk of diabetic foot ulcers and related events. Diabetes, Obesity and Metabolism, 26(9), 3764-3780.

Coppes, T., Philbert, D., van Gelder, T., Bouvy, M. L., & Koster, E. S. (2024). Medication management during sick days: No differences between patients with and without impaired renal function. European Journal of Clinical Investigation, 54(9), Article e14231.

van Nuland, M., Erdogan, A., Aςar, C., Contrucci, R., Hilbrants, S., Maanach, L., Egberts, T., & van der Linden, P. D. (2024). Performance of ChatGPT on Factual Knowledge Questions Regarding Clinical Pharmacy. Journal of Clinical Pharmacology, 64(9), 1095-1100.

Kempen, T. G. H., Benaissa, Y., Molema, H., Valk, L. E., Hazen, A. C. M., Heringa, M., Kwint, H.-F., Zwart, D. L. M., Sporrong, S. K., Stewart, D., & van Dijk, L. (2024). Pharmacists' current and potential prescribing roles in primary care in the Netherlands: a case study. Journal of Interprofessional Care, 38(5), 787-798.

Bennie, M., Santa-Ana-Tellez, Y., Galistiani, G. F., Trehony, J., Despres, J., Jouaville, L. S., Poluzzi, E., Morin, L., Schubert, I., MacBride-Stewart, S., Elseviers, M., Nasuti, P., & Taxis, K. (2024). The prevalence of polypharmacy in older Europeans: A multi-national database study of general practitioner prescribing. British Journal of Clinical Pharmacology, 90(9), 2124-2136.

Ferreira Martins, M. L., Heydari, P., Li, W., Martinez-Chavez, A., el Yattouti, M., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2024). The role of drug efflux and uptake transporters in the plasma pharmacokinetics and tissue disposition of morphine and its main metabolites. Toxicology and Applied Pharmacology, 490, 1-14. Article 117040.

Julian, E., Solà-Morales, O., Garcia, M. J., Brinkhuis, F., Pavlovic, M., Martín-Saborido, C., Doeswijk, R., Giuliani, R., Willemsen, A., Goettsch, W., Wörmann, B., Dafni, U., Bucher, H. C., Pérez-Valderrama, B., Bernardini, R., Gianfrate, F., Uyl-de Groot, C. A., & Ruof, J. (2024). The Role of Medical Societies and the Relevance of Clinical Perspective in the Evolving EU HTA Process: Insights Generated at the 2023 Fall Convention and Survey of the European Access Academy. Journal of market access & health policy, 12(3), 128-143.

on behalf of the COSEB Consortium, Korte, E. W. H., Pasmooij, A. M. G., Bolling, M. C., Hickey, S., Hussain, S., Kiritsi, D., Kottner, J., Prinsen, C. A. C., Sauvestre, A., Sendin, G., Spuls, P. I., Tarrats, N., Wally, V., Welponer, T., Laimer, M., & Van Den Akker, P. C. (2024). Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa. British Journal of Dermatology, 191(3), 463-465.

Arnamo, A. H., Pluim, D., Huitema, A. D. R., Jacobs, B. A. W., Beijnen, J. H., & Nuijen, B. (2024). Prolonged in-use physicochemical and biological stability of nivolumab and pembrolizumab diluted in saline infusion bags and in partially used medication vials. Journal of Oncology Pharmacy Practice. Advance online publication.

Postma, D. J., Heijkoop, M. L. A., De Smet, P. A. G. M., Notenboom, K., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2024). Identifying Medicine Shortages With the Twitter Social Network: Retrospective Observational Study. Journal of Medical Internet Research, 26, Article e51317.

Bloem, L. T., Van der Elst, M. E., & Klungel, O. H. (2024). Principles of Pharmacovigilance and Drug Regulation. In J. Jose, A. R. Cox, & V. Paudyal (Eds.), Principles and Practice of Pharmacovigilance and Drug Safety (pp. 135-161). Springer.

Lentzas, A., de Gooijer, M. C., Zuidema, S., Meurs, A., Çitirikkaya, C. H., Venekamp, N., Beijnen, J. H., & van Tellingen, O. (2024). ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain. Fluids and Barriers of the CNS, 21(1), Article 62.

Ellerbroek, H., Schellekens, A. F. A., Kalkman, G. A., Visser, D. A., Kramers, C., Dahan, A., van den Heuvel, S. A. S., Bouvy, M. L., & van Dorp, E. L. A. (2024). Opioid prescribing in the Netherlands during the COVID-19 pandemic: a national register-based study. BMJ Open, 14(8), Article e082369.

Embaby, A., Huijberts, S. C. F. A., Wang, L., de Oliveira, R. L., Rosing, H., Nuijen, B., Sanders, J., Hofland, I., van Steenis, C., Kluin, R. J. C., Lieftink, C., Smith, C. G., Blank, C. U., van Thienen, J. V., Haanen, J. B. A. G., Steeghs, N., Opdam, F. L., Beijnen, J. H., Huitema, A. D. R., ... Wilgenhof, S. (2024). A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma. Clinical Cancer Research, 30(15), 3157-3166.

Schouten, W. M., Roseboom, I. C., Lucas, L., Kabalu Tshiongo, J., Muhindo Mavoko, H., Kayentao, K., Rosing, H., Huitema, A. D. R., Beijnen, J. H., & Dorlo, T. P. C. (2024). Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of the antimalarial drug pyronaridine in human whole blood. Journal of Pharmaceutical and Biomedical Analysis, 245, Article 116154.

Meertens, M., de Vries, N., Rosing, H., Steeghs, N., Beijnen, J. H., & Huitema, A. D. R. (2024). Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites. Therapeutic Drug Monitoring, 46(4), 494-502.

Manson, L. E. N., Nijenhuis, M., Soree, B., de Boer-Veger, N. J., Buunk, A. M., Houwink, E. J. F., Risselada, A., Rongen, G. A. P. J. M., van Schaik, R. H. N., Swen, J. J., Touw, D. J., van Westrhenen, R., Deneer, V. H. M., & Guchelaar, H. J. (2024). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European Journal of Human Genetics, 32(8), 903-911.

Callenbach, M. H. E., Schoenmakers, D., Vreman, R. A., Vijgen, S., Timmers, L., Hollak, C. E. M., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2024). Illustrating the financial consequences of outcome-based payment models from a payers perspective- the case of autologous gene therapy atidarsagene autotemcel (Libmeldy®). Value in Health, 27(8), 1046-1057.

Tillemans, M. P. H., Giezen, T. J., Egberts, T. C. G., Hooijberg, J. H., & Kalisvaart, K. J. (2024). Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens. British Journal of Clinical Pharmacology, 90(8), 1975-1983.

Sadreghaemy, M., Gamba, M. A., Bloem, L. T., & Egberts, T. C. G. (2024). Leftover of Amoxicillin Suspension After Use by Children in the Netherlands. Pharmacoepidemiology and Drug Safety, 33(8), Article e5868.

Weir, D. L., Bai, Y. Q., Thavorn, K., Guilcher, S., Kanji, S., Mulpuru, S., & Wodchis, W. (2024). Non-adherence to COPD medications and its association with adverse events: A longitudinal population based cohort study of older adults. Annals of Epidemiology, 96, 88-96.

Eroglu, TE., Coronel, R., & Gislason, GH. (2024). Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study. European Heart Journal - Cardiovascular Pharmacotherapy, 10(5), 413-419.

Hoek, J. M., Brenninkmeijer, J., de Vries, Y. A., Meijer, R. R., & van Ravenzwaaij, D. (2024). Assessing the credibility of a drug's effects: identification and judgment of uncertainty by the Dutch Medicines Evaluation Board. Frontiers in Medicine, 11, 1-13. Article 1409259.

Joosse, I. R., van den Ham, H. A., Mantel-Teeuwisse, A. K., Perumal-Pillay, V. A., & Suleman, F. (2024). Access to childhood cancer medicines in South Africa: a health systems analysis of barriers and enablers. Journal of Pharmaceutical Policy and Practice, 17(1), Article 2372033.

Brinkhuis, F., Julian, E., van den Ham, H., Gianfrate, F., Strammiello, V., Berntgen, M., Pavlovic, M., Mol, P., Wasem, J., Van Dyck, W., Cardone, A., Dierks, C., Schiel, A., Bernardini, R., Solà-Morales, O., Ruof, J., & Goettsch, W. (2024). Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health Research Policy and Systems, 22(1), Article 74.

Pieters, T. (2024). ‘Help ik ben besmet’ De illusie doorgeprikt van een ‘intelligente’ lockdown. Tijdschrift Voor Geschiedenis, 137(2), 205-214.

Madrid Paredes, J., Versteeg, J.-W., Vreman, R. A., & Bloem, L. T. (2024). Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations. Clinical Pharmacology and Therapeutics, 116(1), 136-146.